NKAPL Inhibitors
Chemical inhibitors of NKAPL function through diverse molecular mechanisms to disrupt its activity. Alisertib targets the Aurora kinase A, a key regulator of cell cycle progression. By inhibiting this kinase, Alisertib can interfere with the proper cell cycle-dependent functions of NKAPL. Similarly, Palbociclib, a CDK4/6 inhibitor, can halt the cell cycle at the G1 phase, thereby preventing NKAPL from performing its role during cell division. Dasatinib, a Src family kinase inhibitor, can prevent the phosphorylation of substrates necessary for NKAPL activity, thus indirectly inhibiting its function. By targeting these kinases, these inhibitors can disrupt the phosphorylation-dependent processes that are essential for NKAPL activity.
On another front, chemicals like Lenalidomide and Thalidomide modulate the ubiquitin-proteasome system, promoting the degradation of proteins that could regulate or interact with NKAPL, thereby reducing its functional presence. In contrast, proteasome inhibitors such as Bortezomib and MG-132 lead to an accumulation of ubiquitinated proteins, which can indirectly inhibit NKAPL by disrupting protein complexes or signaling pathways essential for its function. In the realm of signal transduction, Omipalisib and LY294002, both PI3K inhibitors, along with Rapamycin, an mTOR inhibitor, can suppress critical survival and proliferation pathways that NKAPL may rely on, leading to its functional inhibition. Additionally, Trametinib and Cobimetinib, both MEK inhibitors, prevent the activation of the MEK/ERK pathway, which is potentially crucial for NKAPL's stability and function. By inhibiting these pathways, these chemicals can effectively reduce NKAPL's activity within cells.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. NKAPL is reported to interact with this kinase, which plays a role in cell cycle regulation. Inhibition of Aurora kinase A by Alisertib could disrupt cell cycle progression and consequently inhibit the function of NKAPL that is dependent on the cell cycle phases. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide has been shown to modulate the ubiquitin-proteasome system. As NKAPL is a protein that may be regulated by ubiquitination, Lenalidomide could promote the degradation of NKAPL through the proteasome pathway, thus functionally inhibiting it. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that would prevent the degradation of ubiquitinated proteins, potentially leading to an accumulation of regulatory proteins that could inhibit NKAPL function indirectly by disrupting its associated protein complexes or signaling pathways. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide, like Lenalidomide, affects the ubiquitin-proteasome system and has been shown to induce the degradation of specific proteins. It could thereby lead to a reduction in protein levels that regulate or interact with NKAPL, resulting in its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can increase cellular levels of ubiquitinated proteins. This can affect the protein degradation pathway and potentially lead to the dysregulation or inhibition of proteins that interact with or regulate NKAPL, thereby inhibiting its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Since Src kinases can phosphorylate a wide range of substrates and are involved in various signaling pathways, inhibition of these kinases could prevent the phosphorylation-dependent activation or interaction of proteins that are necessary for NKAPL function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor which could disrupt the cell cycle. Since NKAPL may have cell cycle-related functions, inhibition of CDK4/6 could lead to cell cycle arrest at the G1 phase, preventing NKAPL from functioning properly during the cell cycle. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $260.00 $1029.00 | ||
Omipalisib is a PI3K/mTOR inhibitor. Inhibition of the PI3K/mTOR pathway can result in reduced cell survival and proliferation signaling, which could subsequently inhibit NKAPL function due to the dependency of NKAPL on these cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in cell growth and metabolism regulation. Inhibition of mTOR can affect the activity of downstream proteins that are essential for the function of NKAPL. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor which prevents the activation of the MEK/ERK pathway. If NKAPL relies on the MEK/ERK pathway for its function or stabilization, then trametinib could inhibit the function of NKAPL by blocking this pathway. | ||||||